Chinese authorities issue operating approval to Siegfried Nantong
This significant site addition to Siegfried’s production network strengthens the company’s long-term competitiveness.
The Chinese Environmental Protection Bureau (EPB) has issued Siegfried Group the final operating approval for its Nantong production site. Consequently, all approvals and certificates required by the authorities for large-scale production have now been obtained. Trial operation for the commercial facilities started a year ago.
Siegfried’s Nantong production site is located in one of China’s most up-to-date industrial parks northwest of Shanghai. The site’s production capacity amounts to 350 cubic meters and provides work for about 200 employees. This significant site addition to Siegfried’s production network in a cost-effective production environment strengthens the company’s long-term competitiveness. The facility was inaugurated in August 2015 and is attracting a great deal of interest from customers.
Dr Walter Kittl, Head Global Operations at Siegfried, said: "Thanks to the final operation approval of the Chinese EPB our production network, and thus our customers, can now profit from a modern multi-purpose plant, complying with highest safety, environmental and quality standards.”
The pilot plants have been producing for 18 months and initial orders for large-scale production have been received. In addition, products will be transferred from other locations to Nantong.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.